Palleon Pharmaceuticals to Present at the Oppenheimer Healthcare Private Company Showcase

WALTHAM, Mass.--(BUSINESS WIRE)-- Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that the company will present at the Oppenheimer Healthcare Private Company Showcase: The Next Wave on Tuesday, October 18, 2022. Jim Broderick, M.D., Chief Executive Officer and founder of Palleon, will present a company overview at 11:45am PT and Palleon will host 1x1 investor meetings, which can be requested through Oppenheimer.

About Palleon Pharmaceuticals
Palleon Pharmaceuticals, co-founded by Nobel laureate Carolyn Bertozzi, is a biotechnology company pioneering glyco-immunology drug development to transform the treatment of cancer and inflammatory diseases. The Company’s proprietary platforms overcome technical barriers unique to glycobiology to enable drug discovery, patient selection, and indication prioritization to de-risk clinical development. The company’s lead program in oncology, E-602, is a Phase 1/2, first-in-class, glyco-immune checkpoint inhibitor which restores antitumor immunity by enzymatically degrading immunosuppressive sialoglycans on hypersialylated tumors and immune cells. Palleon has a rich pipeline of additional drug candidates including several advancing toward IND-enabling studies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005153/en/